Moxifloxacin is a fourth generation synthetic fluoroquinolone antibacterial agent. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase and topoisomerase IV, which is an enzyme necessary to separate bacterial DNA, thereby inhibiting cell replication.
Queen Mary University of London. 2018 Feb.
Targeting APC loss using synthetic lethality in Colorectal Cancer
Moxifloxacin hydrochloride purchased from AbMole
Molecular Weight | 437.89 |
Formula | C21H24FN3O4.HCl |
CAS Number | 186826-86-8 |
Solubility (25°C) | DMSO 80 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] Hung-Jen Tang, et al. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
Related Topoisomerase Products |
---|
ICRF-193
ICRF-193 is an TopoII inhibitor. |
Topoisomerase II inhibitor 15
Topoisomerase II inhibitor 15 is a Topoisomerase II inhibitor. |
Topoisomerase II inhibitor 13
Topoisomerase II inhibitor 13 is a topoisomerase II (Topo II) inhibitor. |
ICRF-196
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193. |
Cholesteryl hemisuccinate
Cholesteryl hemisuccinate is a with hepatoprotective an anticancer activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.